226 related articles for article (PubMed ID: 32402273)
1. SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP.
Davenne T; Klintman J; Sharma S; Rigby RE; Blest HTW; Cursi C; Bridgeman A; Dadonaite B; De Keersmaecker K; Hillmen P; Chabes A; Schuh A; Rehwinkel J
Cell Rep; 2020 May; 31(6):107640. PubMed ID: 32402273
[TBL] [Abstract][Full Text] [Related]
2. Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.
Balakrishnan K; Ravandi F; Bantia S; Franklin A; Gandhi V
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):458-66. PubMed ID: 23773454
[TBL] [Abstract][Full Text] [Related]
3. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
Gandhi V; Kilpatrick JM; Plunkett W; Ayres M; Harman L; Du M; Bantia S; Davisson J; Wierda WG; Faderl S; Kantarjian H; Thomas D
Blood; 2005 Dec; 106(13):4253-60. PubMed ID: 16131572
[TBL] [Abstract][Full Text] [Related]
4. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.
Balakrishnan K; Nimmanapalli R; Ravandi F; Keating MJ; Gandhi V
Blood; 2006 Oct; 108(7):2392-8. PubMed ID: 16778146
[TBL] [Abstract][Full Text] [Related]
5. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.
Balakrishnan K; Burger JA; Quiroga MP; Henneberg M; Ayres ML; Wierda WG; Gandhi V
Blood; 2010 Aug; 116(7):1083-91. PubMed ID: 20442367
[TBL] [Abstract][Full Text] [Related]
6. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
[TBL] [Abstract][Full Text] [Related]
7. Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies.
Furman RR; Hoelzer D
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S29-34. PubMed ID: 18086344
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent.
Gandhi V; Balakrishnan K
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S8-12. PubMed ID: 18086347
[TBL] [Abstract][Full Text] [Related]
9. Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.
Korycka A; Błoński JZ; Robak T
Mini Rev Med Chem; 2007 Sep; 7(9):976-83. PubMed ID: 17897085
[TBL] [Abstract][Full Text] [Related]
10. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
Alonso R; López-Guerra M; Upshaw R; Bantia S; Smal C; Bontemps F; Manz C; Mehrling T; Villamor N; Campo E; Montserrat E; Colomer D
Blood; 2009 Aug; 114(8):1563-75. PubMed ID: 19541822
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.
Balakrishnan K; Verma D; O'Brien S; Kilpatrick JM; Chen Y; Tyler BF; Bickel S; Bantia S; Keating MJ; Kantarjian H; Gandhi V; Ravandi F
Blood; 2010 Aug; 116(6):886-92. PubMed ID: 20427701
[TBL] [Abstract][Full Text] [Related]
12. Comparison of in vivo efficacy of BCX-1777 and cyclosporin in xenogeneic graft-vs.-host disease: the role of dGTP in antiproliferative action of BCX-1777.
Banti S; Miller PJ; Parker CD; Ananth SL; Horn LL; Babu YS; Sandhu JS
Int Immunopharmacol; 2002 Jun; 2(7):913-23. PubMed ID: 12188033
[TBL] [Abstract][Full Text] [Related]
13. GTP is the primary activator of the anti-HIV restriction factor SAMHD1.
Amie SM; Bambara RA; Kim B
J Biol Chem; 2013 Aug; 288(35):25001-25006. PubMed ID: 23880768
[TBL] [Abstract][Full Text] [Related]
14. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.
Homminga I; Zwaan CM; Manz CY; Parker C; Bantia S; Smits WK; Higginbotham F; Pieters R; Meijerink JP
Blood; 2011 Aug; 118(8):2184-90. PubMed ID: 21730354
[TBL] [Abstract][Full Text] [Related]
15. PNP inhibitors selectively kill cancer cells lacking SAMHD1.
Davenne T; Rehwinkel J
Mol Cell Oncol; 2020 Sep; 7(6):1804308. PubMed ID: 33235905
[TBL] [Abstract][Full Text] [Related]
16. SAMHD1 restricts the deoxyguanosine triphosphate pool contributing to telomere stability in telomerase-positive cells.
D'Aronco G; Ferraro P; Sassano V; Dagostino C; Biancotto M; Palumbo E; Presot E; Russo A; Bianchi V; Rampazzo C
FASEB J; 2023 Apr; 37(4):e22883. PubMed ID: 36934410
[TBL] [Abstract][Full Text] [Related]
17. The Deoxynucleoside Triphosphate Triphosphohydrolase Activity of SAMHD1 Protein Contributes to the Mitochondrial DNA Depletion Associated with Genetic Deficiency of Deoxyguanosine Kinase.
Franzolin E; Salata C; Bianchi V; Rampazzo C
J Biol Chem; 2015 Oct; 290(43):25986-96. PubMed ID: 26342080
[TBL] [Abstract][Full Text] [Related]
18. Allosteric regulation of the human and mouse deoxyribonucleotide triphosphohydrolase sterile α-motif/histidine-aspartate domain-containing protein 1 (SAMHD1).
Miazzi C; Ferraro P; Pontarin G; Rampazzo C; Reichard P; Bianchi V
J Biol Chem; 2014 Jun; 289(26):18339-46. PubMed ID: 24828500
[TBL] [Abstract][Full Text] [Related]
19. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.
Robak T; Lech-Maranda E; Korycka A; Robak E
Curr Med Chem; 2006; 13(26):3165-89. PubMed ID: 17168705
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of allosteric activation of SAMHD1 by dGTP.
Ji X; Wu Y; Yan J; Mehrens J; Yang H; DeLucia M; Hao C; Gronenborn AM; Skowronski J; Ahn J; Xiong Y
Nat Struct Mol Biol; 2013 Nov; 20(11):1304-9. PubMed ID: 24141705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
